Stocks on the Move: Real Goods Solar, Inc. (NASDAQ:RSOL), Peregrine Pharmaceuticals (NASDAQ:PPHM)

Posted by Chris Bell May 20, 2013 0 Comment 1786 views


Northern, WI 05/20/2013 (GDPInsider) – Real Goods Solar, Inc. (NASDAQ:RSOL) opened the day’s trading at 4.90 and quickly shot up 50.12% on strong trading volume of 14,064,245 shares. The stock had closed previously at 4.03 and has a range of 4.55 and 6.43. Average volume for RSOL is 252,711 which mean that current market valuation is seeing volume trading increase of 5465.35%.

RSOL which has a market cap of 163.64 million is just coming of its Q1 2013 earnings report. According to its earnings release, Q1 2013 saw an 8% decline in revenues to $16.8 million, compared to the $18.3 million figure recorded in the 1st quarter of 2012. The company did however; report a few positive developments over the quarter, including an increase in solar installations. According to RSOL installations were up 23% resulting in 4.6 megawatts of power being installed over the period. RSOL also expanded into the solar market and ramped up business in California, Massachusetts, New York and Colorado. A new website Shop.RealGoods.com was also launched to help customers have direct access to the company’s products.

RSOL has a rise of 91.19 and is currently trading 214.08% above its SMA20 and 235.83% above its SMA50.

Is RSOL a solid investment at these levels? Get exclusive data and trends here.

Peregrine Pharmaceuticals (NASDAQ:PPHM) is up 25.98% on strong trading today after starting the day at 1.83. PPHM closed previously at 1.54 and the strong start to the day is pegged by a range of 1.76 and 2.06. Volume is up significantly and so far 12.534 million shares have been traded in PPHM. Average volume is 2.309 million and the stock is up 366.67% on its 52-week low of 0.42. PPHM is down 64.36% on its 52-week high of 5.50.

PPHM is well placed in the biopharmaceutical space and develops monoclonal antibodies for the treatment and diagnosis of cancer. The company recently announced an agreement with the U.S. Food and Drug Administration on it should design its late-stage trial for its experimental lung cancer drug. PPHM aims to improve the survival rates of patients afflicted with lung cancer and will compare the combination of chemotherapy and the drug, bavituximab, with chemotherapy alone.

Joseph Shan, VP of clinical and regulatory affairs said that the company was very excited about the agreement: “We look forward to finalizing the clinical protocol and initiating the global Phase III trial by year-end.

PPHM is trading 36.78% above its SMA20 and has a RSI of 82.12.

How Should Investors Trade PPHM Now? Get exclusive insights and updates here.

 

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.

 


About Chris Bell

Chris Bell is an investing reporter for GDP Insider. Chris covers financial markets and Wall Street, concentrating on developments affecting individual investors and their portfolios. Chris is also over consumer reporter and covers a wide variety of issues ranging from housing to immigration to urban poverty. Chris graduated from the University of Scranton with a degree in Communication and Philosophy. Chris's diligent investigations earned him the honor of being named "Best Reporter" once by the Headliners Foundation of Texas and once by the Houston Press Club.

View all post by Chris Bell Visit author's website

Write Your Comment